



TOS 2020 Annual Meeting Continuing Medical Education Information for Learners

Accreditation and Credit for Physicians

The Obesity Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Obesity Society designates this blended learning format activity for a maximum of 94.5 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity combines a live webinar format with optional add-on pre-recorded modules.

Learning Objectives

1. Apply the latest recommendations for evaluation and treatment; tailor intervention strategies based on patient characteristics such as age or metabolic or behavioral phenotype; understand the differences between weight loss and weight loss maintenance.
2. Understand the evidence-based science regarding neuroendocrine, environmental, endocrine, microbiota and/or cognitive behavioral mechanisms regulating energy balance and body weight. Apply that knowledge to develop and implement treatment options for adults and pediatric patients with overweight, obesity or obesity-related comorbidities.
3. Implement appropriate strategies for diagnosing adolescent and pediatric obesity, evaluate current treatment options and emerging therapeutics and provide care and treatment to adolescent and pediatric patients accordingly. Teach evidence-based strategies for obesity prevention in the pediatric and adolescent population.
4. Apply lessons learned about the impact of: nutrition and obesity initiatives to reduce health disparities, and federal nutrition and obesity policies on health disparities.
5. Apply new knowledge related to dietary intervention and physical activity from the perspectives of Metabolism and Integrative Physiology, Neuroscience, Intervention and Clinical Studies, Population Health, Clinical/Professional Practice, and Policy/Public Health.

- Incorporate knowledge about coding for reimbursement into the clinical practice of health care providers to support their ability to treat the underlying disease of overweight and obesity. Incorporate knowledge about best practices to develop and run effective clinics that treat overweight and obesity.

Commercial Support

Educational grant in partial support of the conference was received from Olympus, Rhythm Pharmaceuticals, and W.L. Gore & Associates, Inc.

Faculty and Planning Committee Disclosure Information

The Obesity Society asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relevant relationships with commercial interests. This information is disclosed to CME activity participants. The Obesity Society has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed. TOS requires additional disclosures beyond the ACCME definition of a commercial interest, as indicated by an asterisk in the list below. These include food, weight loss, and supplement industry disclosures. In the list below, the nature of the relationship and company are followed by the industry of that company.

Speaker Disclosures:

| Name | 2020 TOS Annual Meeting Speaker Disclosures |
|--------------------------------|---|
| Abdelmalek, Manal (MD, MPH) | Contracted Research relationship with Intercept (Pharmaceuticals), Allergan (Pharmaceuticals), Celgene (Pharmaceuticals), Bristol Myers Squibb (Pharmaceuticals), NGM Bio (Pharmaceuticals), Inventiva (Pharmaceuticals), Madrigal (Pharmaceuticals), Viking (Pharmaceuticals), Genfit (Pharmaceuticals), Novartis (Pharmaceuticals), Genentech (Pharmaceuticals), Poxel (Pharmaceuticals), Durect (Pharmaceuticals), Boehringer Ingelheim (Pharmaceuticals), Terns (Pharmaceuticals), Hanmi (Pharmaceuticals), Galmed (Pharmaceuticals), Target NASH (Pharmaceuticals), Novo Nordisk (Pharmaceuticals); Consulting Fee relationship with Hanmi (Pharmaceuticals), Madrigal (Pharmaceuticals), Intercept (Pharmaceuticals), NGM (Pharmaceuticals), BMS (Pharmaceuticals), TaiwanJ (Pharmaceuticals), Novo Nordisk (Pharmaceuticals), Inventiva (Pharmaceuticals) |
| Acosta, Andres (MD, PhD, ABOM) | Consulting Fee relationship with Rhythm Pharmaceuticals (Pharmaceuticals) and General Mills (Food)* |
| Aghababian, Anahys | No Relevant Financial Relationships |
| Aguilera, Juan (MD, PhD, MPH) | No Relevant Financial Relationships |
| Al Ozairi, Ebaa (MD) | No Relevant Financial Relationships |
| Allison, Kelly (PhD) | PI of investigator-initiated study relationship with Novo Nordisk (Pharmaceuticals) |
| Almandoz, Jaime (MD, MBA) | No Relevant Financial Relationships |

| Name | 2020 TOS Annual Meeting Speaker Disclosures |
|--|--|
| Ames, Gretchen (PhD) | No Relevant Financial Relationships |
| Anderson Steeves, Betsy (PhD, RDN) | No Relevant Financial Relationships |
| Apovian, Caroline (MD) | Contracted Research relationship with Novo Nordisk and with Gelesis; Ownership Interest (stock) relationship with Gelesis; Consulting Fee relationship with Nutritsystem, Zafgen, Sanofi-Aventis, Novo Nordisk, Scientific Intake, Xeno Biosciences, Rhythm Pharmaceuticals and Bariatrix Nutrition |
| Ard, Jamy (MD, FTOS) | Corporate Advisory Board relationship with Novo Nordisk (Pharmaceuticals) and Amgen (Pharmaceuticals); Consulting Fee relationship with Nestle Healthcare Nutrition (Weight Management)* and Boehringer Ingelheim (Pharmaceuticals) |
| Armstrong, Sarah (MD) | No Relevant Financial Relationships |
| Aronne, Louis (MD, FACP, FTOS, DABOM) | Consulting Fee relationship with Jamieson Laboratories (Supplement)*, Real Appeal (Weight Management)*, Eisai (Pharmaceuticals), Gelesis (Biotech), Pfizer (Pharmaceuticals), Novo Nordisk (Pharmaceuticals), and Janssen (Pharmaceuticals); Contracted Research relationship with Novo Nordisk (Pharmaceuticals), Janssen (Pharmaceuticals), Aspire Bariatrics (Medical Device), Allurion (Medical Device), AstraZeneca (Pharmaceuticals), Gelesis (Biotech), and Eisai (Pharmaceuticals); Corporate Advisory Board relationship with Real Appeal (Weight Management)*, Jamieson Laboratories (Supplement)*, Pfizer (Pharmaceuticals), Eisai (Pharmaceuticals), Janssen (Pharmaceuticals) and Novo Nordisk (Pharmaceuticals); Ownership Interest (stock) relationship with BMIQ (Weight Management)*, Zafgen (Pharmaceuticals), Gelesis (Pharmaceuticals), Myos Corp (Supplement)*, ERX (Pharmaceuticals) and Jamieson Laboratories (Supplement)*; Board of Directors relationship with Myos Corp (Supplement)*, Jamieson Laboratories (Supplement)*, and BMIQ (Weight Management)* |
| Balantekin, Katherine (PhD, RD) | No Relevant Financial Relationships |
| Bales, Michelle (PhD) | No Relevant Financial Relationships |
| Barnes, Evette (RD, MPH) | No Relevant Financial Relationships |
| Bass, Joe (MD) | No Relevant Financial Relationships |
| Berger, Paige (PhD, RD) | No Relevant Financial Relationships |
| Berlin, David (MD) | Consulting Fee relationship with Bristol Myers Squibb (Pharmaceuticals) |
| Bessesen, Daniel (MD) | No Relevant Financial Relationships |
| Bettigole, Cheryl (MD, MPH) | No Relevant Financial Relationships |
| Beutler, Lisa (MD, PhD) | No Relevant Financial Relationships |
| Blackstone, Robin (MD, FACS, Certified Diplomate ABOM) | Corporate Advisory Board relationship with Johnson and Johnson Institute (Education); Speakers Bureau relationship with Ethicon Endosurgery (Medical Device) |
| Blanck, Heidi (PhD) | No Relevant Financial Relationships |
| Bleich, Sara (PhD) | No Relevant Financial Relationships |
| Blondin, Denis (PhD) | No Relevant Financial Relationships |
| Bloyd, Michelle (BS) | No Relevant Financial Relationships |

| Name | 2020 TOS Annual Meeting Speaker Disclosures |
|--------------------------------------|---|
| Bray, George (MD) | Corporate Advisory Board relationship with Medifast (Weight Management)* |
| Brown, Alison (PhD, MS) | No Relevant Financial Relationships |
| Browning, Kirsteen (PhD) | No Relevant Financial Relationships |
| Buras, Eric (MD, PhD) | No Relevant Financial Relationships |
| Buscemi, Joanna (PhD) | No Relevant Financial Relationships |
| Cabeza de Baca, Tomas (PhD) | No Relevant Financial Relationships |
| Cady, Barbara | No Relevant Financial Relationships |
| Callaway, Katherine (MPH) | No Relevant Financial Relationships |
| Calouro, Christine | No Relevant Financial Relationships |
| Cannon, Barbara (PhD) | No Relevant Financial Relationships |
| Cardel, Michelle (PhD, MS, RD) | No Relevant Financial Relationships |
| Carnell, Susan (PhD) | No Relevant Financial Relationships |
| Cero, Cheryl (PhD) | No Relevant Financial Relationships |
| Chauvenet, Christina (PhD) | No Relevant Financial Relationships |
| Chen, Eunice (PhD) | No Relevant Financial Relationships |
| Chen, Liuyi | No Relevant Financial Relationships |
| Chometton, Sandrine | No Relevant Financial Relationships |
| Coen, Paul (PhD) | No Relevant Financial Relationships |
| Cohen, Ricardo (PhD, MD) | Research Grant relationship with Johnson&Johnson Medical (Medical Device) |
| Cohen, Juliana (ScD, MSc) | No Relevant Financial Relationships |
| Conroy, Molly (MD, MPH, FACSM, FAHA) | No Relevant Financial Relationships |
| Corvera, Silvia (MD) | No Relevant Financial Relationships |
| Crandall, Amanda (MS) | No Relevant Financial Relationships |
| Crochiere, Rebecca (MS) | No Relevant Financial Relationships |
| Crowley, Nina (PhD, RDN, LD) | No Relevant Financial Relationships |
| Danforth, Rick (SM(ASCP)) | No Relevant Financial Relationships |
| Decker, Kristina (PhD) | No Relevant Financial Relationships |
| Dhurandhar, Emily (PhD) | Ownership Interest (stock) relationship with Dhurandhar Weight Management (Weight Management)* and Metabologix, LLC (Weight Management)* |
| Dietz, William (MD, PhD, FTOS) | Consulting Fee relationship with weight watchers (WW) adolescent advisory board (Weight Management)*; Contracted Research relationship with Novo Nordisk (Pharmaceuticals) |
| Donovan, Sharon (PhD, RD) | Consulting Fee relationship with ByHeart (Food)* and Danone North America & Danone Institutes International (Food)*; Speakers Bureau relationship with Nestle Nutrition Institute (Food)* |
| Drucker, Daniel (MD) | Consulting Fee relationship with Intarcia (Biotech), Merck (Pharmaceuticals), Novo Nordisk (Pharmaceuticals) and Pfizer (Pharmaceuticals) |

| Name | 2020 TOS Annual Meeting Speaker Disclosures |
|--|---|
| Duffy, Emily (MPH, RD) | No Relevant Financial Relationships |
| Dunaif, Andrea (MD) | Consulting Fee relationship with Fractyl Laboratories, Inc (Medical Device) and Equator Therapeutics (Biotech) |
| Eagleton, Sally (MS) | No Relevant Financial Relationships |
| Economos, Christina (PhD) | No Relevant Financial Relationships |
| Elmquist, Joel (DVM, PhD) | Consulting Fee relationship with Merck (Pharmaceuticals) and Johnson & Johnson (Pharmaceuticals); Sponsored Research Agreement relationship with Pfizer (Pharmaceuticals) |
| Escobar, Carolina (PhD) | No Relevant Financial Relationships |
| Essman, Michael (MSc) | No Relevant Financial Relationships |
| Estabrooks, Paul (PhD) | No Relevant Financial Relationships |
| Fang, Lisa | No Relevant Financial Relationships |
| Farooqi, Sadaf (MBChB (Hons), PhD, FRCP, FMedSci, DSc) | No Relevant Financial Relationships |
| Fennoy, Ilene (MD, MPH) | No Relevant Financial Relationships |
| Ferrario, Carrie (PhD) | No Relevant Financial Relationships |
| Fisher, Jennifer (PhD) | Consulting Fee relationship with WW International Inc (Weight Management)* |
| Fitch, Angela (MD) | Corporate Advisory Board relationship with Set Point Health (Weight Management)* |
| Flanagan, Emily (PhD) | No Relevant Financial Relationships |
| Fowler, Lauren (PhD) | No Relevant Financial Relationships |
| Fowler, Lauren (PhD) | No Relevant Financial Relationships |
| Fried, Susan (PhD) | No Relevant Financial Relationships |
| Fulkerson, Jayne (PhD) | No Relevant Financial Relationships |
| Gabel, Kelsey (PhD, RD, LDN) | No Relevant Financial Relationships |
| Gallagher, Isabelle (BS) | No Relevant Financial Relationships |
| Gavin, Kathleen (PhD) | Ownership Interest (stock) relationship with Energy Balance Nutrition Consulting (Weight Management)* and The Science of Dieting (Weight Management)* |
| Gay, Roxane | No Relevant Financial Relationships |
| Geisler, Caroline (PhD) | No Relevant Financial Relationships |
| Genkinger, Jeanine (PhD) | No Relevant Financial Relationships |
| Gibson, Laura (PhD) | No Relevant Financial Relationships |
| Goodman, Alyson (MD, MPH) | No Relevant Financial Relationships |
| Goodpaster, Kasey (PhD) | No Relevant Financial Relationships |
| Gordon-larsen, Penny (PhD, FTOS) | No Relevant Financial Relationships |
| Grill, Harvey (PhD) | No Relevant Financial Relationships |
| Grummon, Anna (PhD, MSPH) | No Relevant Financial Relationships |

| Name | 2020 TOS Annual Meeting Speaker Disclosures |
|---------------------------------------|---|
| Grunvald, Eduardo (MD, FACP) | Consulting Fee relationship with Novo Nordisk (Pharmaceuticals) |
| Guler, Ali (PhD) | No Relevant Financial Relationships |
| Hall, Marissa (PhD, MSPH) | No Relevant Financial Relationships |
| Hardaway, Andrew (PhD) | No Relevant Financial Relationships |
| Harris, David | No Relevant Financial Relationships |
| Hayes, Matthew (PhD) | Contracted Research relationship with Zealand Pharma (Pharmaceuticals), Boehringer-Ingelheim (Pharmaceuticals), Novo Nordisk (Pharmaceuticals) and Eli Lilly & Co. (Pharmaceuticals); Ownership Interest (stock) relationship with Cantius Therapeutics (Biotech) |
| Hayes, Jacqueline (PhD) | No Relevant Financial Relationships |
| Heinberg, Leslie (PhD) | No Relevant Financial Relationships |
| Hes, Dyan (MD) | Speakers Bureau relationship with Abbott Nutrition (Pharmaceuticals); Consulting Fee relationship with Pfizer (Pharmaceuticals) and Grain Foods Foundation (Food)* |
| Hoechsmann, Christoph (PhD) | No Relevant Financial Relationships |
| Hoelscher, Deanna (PhD, RDN, LD, CNS) | No Relevant Financial Relationships |
| Holgerson, Allison (PhD) | No Relevant Financial Relationships |
| Holt, Marie (PhD) | No Relevant Financial Relationships |
| Hursting, Stephen (PhD, MPH, RD) | No Relevant Financial Relationships |
| Husain, Farah (MD, FACS, FASMBS) | No Relevant Financial Relationships |
| Jastreboff, Ania (MD, PhD) | Contracted Research relationship with Novo Nordisk (Pharmaceuticals), Boehringer (ngelheim (Pharmaceuticals) and Eil Lilly (Pharmaceuticals); Consulting Fee relationship with Novo Nordisk (Pharmaceuticals), ClearView Healthcare Partners (Pharmaceuticals) and Eli Lilly (Pharmaceuticals) |
| Jay, Melanie (MD, MS) | No Relevant Financial Relationships |
| Jirapinyo, Pichamol (MD, MPH) | No Relevant Financial Relationships |
| Kahan, Scott (MD, MPH, FTOS) | Consulting Fee relationship with Novo Nordisk (Pharmaceuticals) and Vivus (Pharmaceuticals) |
| Kaplan, Lee (MD, PhD, FTOS) | Consulting Fee relationship with Johnson & Johnson; Consulting Fee relationship with Novo Nordisk; Consulting Fee relationship with Rhythm; Consulting Fee relationship with GI Dynamics; Royalty relationship with Whole Biome; Consulting Fee relationship with Boehringer Ingelheim (Pharmaceuticals); Consulting Fee relationship with Pfizer (Pharmaceuticals) |
| Kapoor, Ekta (MBBS) | Consulting Fee relationship with Astellas Phramaceuticals (Pharmaceuticals); honorarium for lecture relationship with CogniMed (Pharmaceuticals) |
| Katzmarzyk, Peter (PhD) | No Relevant Financial Relationships |
| Keel, Pamela (PhD) | No Relevant Financial Relationships |
| Keller, Evan (BS) | No Relevant Financial Relationships |

| Name | 2020 TOS Annual Meeting Speaker Disclosures |
|-------------------------------------|---|
| Kidambi, Srividya (MD) | Local PI for SEPRA trial. relationship with Novo Nordisk (Pharmaceuticals) |
| Kim, Ki-Suk (PhD) | No Relevant Financial Relationships |
| Kim, Eric (BA) | No Relevant Financial Relationships |
| Kliewer, Steven | Provided recombinant FGF21 protein for research relationship with Novo Nordisk (Pharmaceuticals); Ownership Interest (stock) relationship with Atias Pharmaceuticals (Biotech) |
| Koball, Afton (PhD, ABPP) | No Relevant Financial Relationships |
| Kracht, Chelsea (PhD) | No Relevant Financial Relationships |
| Krakoff, Jonathan (MD) | No Relevant Financial Relationships |
| Kramer, Holly (MD) | No Relevant Financial Relationships |
| Kreitinger, Kimberly (MD) | No Relevant Financial Relationships |
| Kumanyika, Shiriki (PhD, MPH, FTOS) | No Relevant Financial Relationships |
| Kumar, Rekha (MD) | No Relevant Financial Relationships |
| Kyle, Theodore (RPh, MBA) | Consulting Fee relationship with Novo Nordisk (Pharmaceuticals) and Gelesis (Medical Device); Corporate Advisory Board relationship with Nutrasystem (Weight Management)* |
| Landry, Taylor (MS) | No Relevant Financial Relationships |
| Laughlin, Maren (PhD) | No Relevant Financial Relationships |
| Lazarus, Jeremy (MD) | No Relevant Financial Relationships |
| Lazarus, Ethan (MD, FOMA) | Speakers Bureau relationship with Novo Nordisk (Pharmaceuticals) |
| Le Roux, Carel (MD, PhD) | Corporate Advisory Board relationship with NovoNordisk (Pharmaceuticals), Johnson&Johnson (Medical Device), Herbalife (Food)*, Keyron (Medical Device) and GI Dynamics (Medical Device) |
| Lee, Alexandra (BS) | No Relevant Financial Relationships |
| Lee, Karen (MD, MHSc, FRCPC) | No Relevant Financial Relationships |
| Leibel, Rudolph (MD) | No Relevant Financial Relationships |
| LeMay-Russell, Sarah (MS) | No Relevant Financial Relationships |
| Lessard, Leah (PhD) | No Relevant Financial Relationships |
| Liss, Don (MD) | No Relevant Financial Relationships |
| Liu, En Yong | No Relevant Financial Relationships |
| Lowery, Caitlin (MSPH) | No Relevant Financial Relationships |
| Lumeng, Julie (MD) | No Relevant Financial Relationships |
| MacEwan, Joanna (PhD) | Contracted Research relationship with Eli Lilly (Pharmaceuticals) |
| Martins, Catia | No Relevant Financial Relationships |
| Massie, Nikki | No Relevant Financial Relationships |
| Mathews, Anne (PhD, RDN) | No Relevant Financial Relationships |
| Mattern, Marie | No Relevant Financial Relationships |
| Mazzone, Christopher (PhD) | No Relevant Financial Relationships |
| McCarthy, John (PhD) | No Relevant Financial Relationships |
| Mistler, Colleen | No Relevant Financial Relationships |

| Name | 2020 TOS Annual Meeting Speaker Disclosures |
|---|--|
| Mitchell, Nia (MD, MPH) | No Relevant Financial Relationships |
| Molofsky, Ari (MD PhD) | No Relevant Financial Relationships |
| Moon, Rena (MD, MPH) | No Relevant Financial Relationships |
| Morrison, Christopher (PhD) | No Relevant Financial Relationships |
| Morton, John (MD, MPH, MHA, FACS, FASMBS, ABOM) | Consulting Fee relationship with Medtronic (Medical Device) and Ethicon (Medical Device) |
| Mostaghim, Anahita (MD) | No Relevant Financial Relationships |
| Musicus, Aviva (ScD) | No Relevant Financial Relationships |
| Nadglowski, Joseph (BS) | No Relevant Financial Relationships |
| Newlin, Kim (RN, CNS, ANP-C) | Consulting Fee relationship with Boehringer Ingelheim (Pharmaceuticals) |
| Newsome, Faith | Speakers Bureau relationship with Novo Nordisk (Pharmaceuticals) |
| Newsome, Shannon | No Relevant Financial Relationships |
| Norian, Lyse (PhD) | No Relevant Financial Relationships |
| O'Connor, Richard (PhD) | No Relevant Financial Relationships |
| Pagoto, Sherry (PhD) | Contracted Research relationship with Weight Watchers International (Weight Management)*; scientific advisor relationship with Fitbit (digital health) |
| Pandit, Bilal | No Relevant Financial Relationships |
| Pannain, Silvana (MD) | Speakers Bureau relationship with Novo Nordisk (Pharmaceuticals) |
| Papantoni, Afroditi (BS) | No Relevant Financial Relationships |
| Pate, Russell (PhD) | No Relevant Financial Relationships |
| Pattou, Francois | No Relevant Financial Relationships |
| Perez-Bonilla, Patricia | No Relevant Financial Relationships |
| Petimar, Joshua (ScD) | No Relevant Financial Relationships |
| Phelan, Suzanne (PhD) | Contracted Research relationship with WW (Weight Management)* |
| Popkin, Barry (PhD) | No Relevant Financial Relationships |
| Potthoff, Matthew (PhD) | No Relevant Financial Relationships |
| Prado, Wagner | No Relevant Financial Relationships |
| Primack, Craig (MD, FACP, FAAP, FOMA) | Consulting Fee relationship with Contrave (Pharmaceuticals), Nestle (Food)* and Gelesys (Medical Device); Speakers Bureau relationship with Novo Nordisk (Pharmaceuticals); Stock relationship with Vivus (Pharmaceuticals); advisory board relationship with Phenomix (Biotech) |
| Proietto, Joseph (MBBS PhD) | Contracted Research relationship with Zafgen (Pharmaceuticals) |
| Quader, Zerleen | No Relevant Financial Relationships |
| Ravichandran, Soumya | No Relevant Financial Relationships |
| Raybould, Helen (PhD) | No Relevant Financial Relationships |
| Renquist, Benjamin | Ownership Interest (stock) relationship with LivEndocrine, LLC (Pharmaceuticals) and LivEndocrine, LLC (Pharmaceuticals) |
| Reyes, Marcela (MD, MSc, PhD) | No Relevant Financial Relationships |
| Rieder, Jessica (MD, MS) | No Relevant Financial Relationships |

| Name | 2020 TOS Annual Meeting Speaker Disclosures |
|--|--|
| Rimm, Eric (ScD) | Scientific Advisory Board relationship with USDA/US Highbush Blueberry Council (Food)* |
| Roberts, Michael (JD, LLM) | No Relevant Financial Relationships |
| Rogers, Renee (PhD) | Contracted Research relationship with Weight Watchers International, Inc. (Weight Management)* |
| Rosenbaum, Michael (MD) | No Relevant Financial Relationships |
| Rummo, Pasquale (MPH, PhD) | No Relevant Financial Relationships |
| Ruzicka, Elizabeth (PhD) | No Relevant Financial Relationships |
| Safford, Monika (MD) | Contracted Research relationship with Amgen (Pharmaceuticals) |
| Salehi, Parisa (MD) | Contracted Research relationship with Soleno Therapeutics, Inc (Pharmaceuticals) and Millendo Therapeutics, Inc. (Pharmaceuticals) |
| Sandoval, Darleen (PhD) | No Relevant Financial Relationships |
| Santos, Melissa (PhD) | No Relevant Financial Relationships |
| Saunders, Katherine (MD) | Ownership Interest (stock) relationship with Intellihealth (Weight Management)* |
| Saxon, David (MD, MS) | No Relevant Financial Relationships |
| Schellinger, Jeffrey (MCN, RDN, CSOWM) | No Relevant Financial Relationships |
| Scherer, Philipp (PhD) | No Relevant Financial Relationships |
| Schick, Alex | No Relevant Financial Relationships |
| Schneider, Glenn (MPH) | No Relevant Financial Relationships |
| Schulman, Allison (MD MPH) | Consulting Fee relationship with Apollo Endosurgery (Medical Device), Boston Scientific (Medical Device) and MicroTech (Medical Device); Research support relationship with GI Dynamics (Medical Device) |
| Segrest, Valerie | No Relevant Financial Relationships |
| Shaffer, Forrest | No Relevant Financial Relationships |
| Shaikh, Raz | Contracted Research relationship with Organic Technologies (Supplement)* |
| Shank, Lisa (PhD, MPH) | No Relevant Financial Relationships |
| Shankar, Kripa (PhD) | No Relevant Financial Relationships |
| Sharma, Arya (MD, DSc (hon), FRCPC) | Consulting Fee relationship with Novo Nordisk (Pharmaceuticals) |
| Shearrer, Grace (PhD) | No Relevant Financial Relationships |
| Skinner, Asheley (PhD) | No Relevant Financial Relationships |
| Sogg, Stephanie (PhD) | No Relevant Financial Relationships |
| Spaeth, Andrea (PhD) | No Relevant Financial Relationships |
| Speakman, John (PhD, FTOS) | No Relevant Financial Relationships |
| Spring, Bonnie (PhD) | No Relevant Financial Relationships |
| Srivastava, Gitanjali (MD, FACP, FAAP) | Consulting Fee relationship with Rhythm Pharmaceuticals (Pharmaceuticals) and Novo Nordisk (Pharmaceuticals) |

| Name | 2020 TOS Annual Meeting Speaker Disclosures |
|--|--|
| Stanford, Fatima Cody (MD, MPH, MPA, FAAP, FACP, FAHA, FTOS) | Corporate Advisory Board relationship with Novo Nordisk (Pharmaceuticals) |
| Steele, Catherine (PhD) | No Relevant Financial Relationships |
| Steger, Felicia (PhD, MS, RD) | No Relevant Financial Relationships |
| Stephens, Jacqueline (PhD) | No Relevant Financial Relationships |
| Stinson, Emma (MPH) | No Relevant Financial Relationships |
| Suarez, Lilianna (MPH) | No Relevant Financial Relationships |
| Sullivan, Shelby (MD) | Contracted Research relationship with Allurion Technologies (Medical Device), Aspire Bariatrics (Medical Device), BARONova (Medical Device), Elira (Medical Device) and Obalon (Medical Device); Consulting Fee relationship with Obalon (Medical Device), Nitinotes Surgical (Medical Device), Allurion Technologies (Medical Device), Endo Tools (Medical Device), Phenomix Sciences (Biotech) and Elira (Medical Device); Ownership Interest (stock) relationship with Elira (Medical Device) |
| Swift, Damon (PhD) | No Relevant Financial Relationships |
| Szalanczy, Alexandria | No Relevant Financial Relationships |
| Tabas, Ira (MD, PhD) | No Relevant Financial Relationships |
| Tamashiro, Kellie (PhD) | No Relevant Financial Relationships |
| Taylor, Roy (BSc, MB ChB, MD, FRCP, FRCPE) | Speakers Bureau relationship with Lecture sponsored by Eli Lilly (Pharmaceuticals) |
| Thapaliya, Gita (PhD) | No Relevant Financial Relationships |
| Thompson, Christopher (MD) | Consulting Fee relationship with Apollo Endosurgery (Medical Device) and USGI Medical (Medical Device); Contracted Research relationship with USGI Medical (Medical Device) and Apollo Endosurgery (Medical Device) |
| Tremblay, Mark (PhD, MSc) | No Relevant Financial Relationships |
| Tsai, Adam (MD, MSCE, FACP) | No Relevant Financial Relationships |
| Tsoukas, Michael (MD) | No Relevant Financial Relationships |
| Turner-McGrievy, Brie (PhD, MS, RD, FTOS) | No Relevant Financial Relationships |
| Twells, Laurie (PhD) | No Relevant Financial Relationships |
| van Diepen, Rianne | No Relevant Financial Relationships |
| Wadden, Thomas (PhD) | Scientific Advisory Board relationship with Novo Nordisk (Pharmaceuticals) and WW (Weight Watchers) (Weight Management)*; Grant relationship with WW (Weight Watchers) (Weight Management)* |
| Warren, Kimberly (PhD) | No Relevant Financial Relationships |
| Whigham, Leah (PhD, FTOS) | No Relevant Financial Relationships |
| Whyte, Kathryn (PhD, RD) | No Relevant Financial Relationships |
| Wilfley, Denise (PhD) | No Relevant Financial Relationships |
| Willis, Erik (PhD, MPH) | No Relevant Financial Relationships |
| Wing, Rena (PhD) | No Relevant Financial Relationships |

| Name | 2020 TOS Annual Meeting Speaker Disclosures |
|----------------------------|--|
| Wright, Jonathan (MD, PhD) | clinical trial PI relationship with Merck (Pharmaceuticals), Nucleix (Medical Device), and Altor Biosciences (Pharmaceuticals); Royalty relationship with UpToDate (Biotech) |
| Yanovski, Susan (MD, FTOS) | Contracted Research relationship with Rhythm Pharmaceuticals (Pharmaceuticals) and Soleno Therapeutics (Pharmaceuticals) |
| Yeo, Giles (PhD) | No Relevant Financial Relationships |
| Zeller, Meg (PhD) | No Relevant Financial Relationships |
| Zepp, Erin (MS, RD, CDCES) | No Relevant Financial Relationships |
| Zunica, Elizabeth (MS) | No Relevant Financial Relationships |

* Denotes TOS-required disclosures of relationships with food, supplement, or weight management companies.

Planner Disclosures: TOS Annual Meeting Program Committee disclosures:

| Name | Role | 2020 TOS Annual Meeting Planner Disclosures |
|--------------------------------|---|---|
| Agurs-Collins, Tanya (PhD, RD) | T4: Population Health | No Relevant Financial Relationships |
| Allison, Kelly (PhD) | T3: Intervention/Clinical Studies Chair | PI of investigator-initiated study relationship with Novo Nordisk (Pharmaceuticals) |
| Almandoz, Jaime (MD, MBA) | Co-Chair | No Relevant Financial Relationships |
| Butsch, Scott (MD MSc FTOS) | T5: Clinical/Professional Practice | Consulting Fee relationship with Novo Nordisk (Pharmaceuticals) and Rhythm Pharmaceuticals (Pharmaceuticals) |
| Cardel, Michelle (PhD, MS, RD) | T4: Population Health Chair | No Relevant Financial Relationships |
| Carnell, Susan (PhD) | T4: Population Health Co-Chair | No Relevant Financial Relationships |
| Chen, Kong (PhD, MSCI) | T1: Metabolism/Integrative Physiology | No Relevant Financial Relationships |
| Comuzzie, Anthony (PhD, FTOS) | TOS CEO | Consulting Fee relationship with Novo Nordisk (Pharmaceuticals) |
| Donahoo, William (MD) | T3: Intervention/Clinical Studies | No Relevant Financial Relationships |
| Goldman, Rachel (PhD) | T5: Clinical/Professional Practice | No Relevant Financial Relationships |
| Grothe, Karen (PhD) | T5: Clinical/Professional Practice Co-Chair | No Relevant Financial Relationships |
| Hayes, Matthew (PhD) | Chair | Contracted Research relationship with Zealand Pharma (Pharmaceuticals), Boehringer-Ingelheim (Pharmaceuticals), Novo Nordisk (Pharmaceuticals) and Eli Lilly & Co. (Pharmaceuticals); Ownership Interest (stock) relationship with Cantius Therapeutics (Biotech) |

| Name | Role | 2020 TOS Annual Meeting Planner Disclosures |
|-------------------------------|--|--|
| Igel, Leon (MD, FACP, FTOS) | T3: Intervention/Clinical Studies Co-Chair | Consulting Fee relationship with Novo Nordisk (Pharmaceuticals); Ownership Interest (stock) relationship with Intellihealth (Weight Management) |
| Jastreboff, Ania (MD, PhD) | T2: Neuroscience Co-Chair | Contracted Research relationship with Novo Nordisk (Pharmaceuticals), Boehringer Ingelheim (Pharmaceuticals) and Eli Lilly (Pharmaceuticals); Consulting Fee relationship with Novo Nordisk (Pharmaceuticals), ClearView Healthcare Partners (Pharmaceuticals) and Eli Lilly (Pharmaceuticals) |
| Kaplan, Lee (MD, PhD, FTOS) | Liaison | Consulting Fee relationship with Johnson & Johnson (Medical Device), Novo Nordisk (Pharmaceuticals), Rhythm (Pharmaceuticals), GI Dynamics (Medical Device), Boehringer Ingelheim (Pharmaceuticals) and Pfizer (Pharmaceuticals); Royalty relationship with Whole Biome |
| Kotz, Catherine (PhD) | Liaison | No Relevant Financial Relationships |
| Krashes, Michael (PhD) | T2: Neuroscience | No Relevant Financial Relationships |
| Lawman, Hannah (PhD) | T6: Policy/Public Health | No Relevant Financial Relationships |
| Leininger, Gina (PhD) | T2: Neuroscience | No Relevant Financial Relationships |
| Lewis, Kristina (MD, MPH, SM) | T6: Policy/Public Health Chair | No Relevant Financial Relationships |
| Lowe, Michael (PhD) | T3: Intervention/Clinical Studies | Consulting Fee relationship with The Renfrew Center for eating disorders (Eating disorders treatment) |
| Melanson, Edward (PhD) | T1: Metabolism/Integrative Physiology | No Relevant Financial Relationships |
| Messiah, Sarah (PhD, MPH) | T4: Population Health | No Relevant Financial Relationships |
| Mittendorfer, Bettina | T3: Intervention/Clinical Studies | No Relevant Financial Relationships |
| Moran, Alyssa (ScD, MPH, RD) | T6: Policy/Public Health Co-Chair | No Relevant Financial Relationships |
| Musicus, Aviva (ScD) | T6: Policy/Public Health | No Relevant Financial Relationships |
| Nicastro, Holly (PhD, MPH) | T4: Population Health | No Relevant Financial Relationships |
| Ogunkua, Lanese | T5: Clinical/Professional Practice | No Relevant Financial Relationships |
| Peters, James (PhD) | T2: Neuroscience Chair | No Relevant Financial Relationships |
| Raynor, Hollie (PhD) | Liaison | No Relevant Financial Relationships |
| Rector, R. Scott (PhD, FTOS) | T1: Metabolism/Integrative Physiology | No Relevant Financial Relationships |
| Roberto, Christina (PhD) | T6: Policy/Public Health | No Relevant Financial Relationships |

| Name | Role | 2020 TOS Annual Meeting Planner Disclosures |
|------------------------|--|---|
| Shukla, Alpana (MD) | T5: Clinical/Professional Practice Chair | No Relevant Financial Relationships |
| Smith Jr, Daniel (PhD) | T1: Metabolism/Integrative Physiology Chair | No Relevant Financial Relationships |
| Suarez, Andrea | T2: Neuroscience | No Relevant Financial Relationships |
| White, Ursula (PhD) | T1: Metabolism/Integrative Physiology Co-Chair | No Relevant Financial Relationships |
| Williams, Diana (PhD) | T2: Neuroscience | No Relevant Financial Relationships |

* Denotes TOS-required disclosures of relationships with food, supplement, or weight management companies.

Reviewer Disclosures: No members of the TOS CME Oversight Committee, charged with the resolution of all relevant conflicts of interest, had any relevant financial relationships while serving on the committee. One committee member did step down upon developing a potential conflict.

| Name | Role | 2020 TOS Annual Meeting Review Disclosure |
|------------------|------------------------|--|
| Cleek, John (MD) | Former Committee Chair | Stepped down April 2020 after accepting a consulting relationship with Boehringer Ingelheim (Pharmaceutical). Prior to that date, had no relevant financial relationships. |

Disclaimer

These materials and all other materials provided in conjunction with continuing medical education activities are intended solely for the purposes of supplementing continuing medical education programs for qualified health care professionals. Anyone using the materials assumes full responsibility and all risk for their appropriate use. The Obesity Society makes no warranties or representations whatsoever regarding the accuracy, completeness, currentness, noninfringement, merchantability or fitness for a particular purpose of the materials. In no event will The Obesity Society be liable to anyone for any decision made or action taken in reliance on the materials. In no event should the information in the materials be used as a substitute for professional care.

This document was last updated October 31, 2020.